MX2020001790A - Preparacion de exosomas terapeuticos mediante el uso de proteinas de membrana. - Google Patents
Preparacion de exosomas terapeuticos mediante el uso de proteinas de membrana.Info
- Publication number
- MX2020001790A MX2020001790A MX2020001790A MX2020001790A MX2020001790A MX 2020001790 A MX2020001790 A MX 2020001790A MX 2020001790 A MX2020001790 A MX 2020001790A MX 2020001790 A MX2020001790 A MX 2020001790A MX 2020001790 A MX2020001790 A MX 2020001790A
- Authority
- MX
- Mexico
- Prior art keywords
- exosomes
- proteins
- exosome
- preparation
- membrane proteins
- Prior art date
Links
- 210000001808 exosome Anatomy 0.000 title abstract 9
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 108010052285 Membrane Proteins Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 4
- 238000001261 affinity purification Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N2509/10—Mechanical dissociation
Abstract
La presente invención se refiere a métodos para preparar un exosoma terapéutico usando una proteína recientemente identificada para ser enriquecida en la superficie de exosomas. Específicamente, la presente invención proporciona métodos para usar las proteínas para purificación de afinidad de exosomas. También proporciona métodos para ubicar un péptido terapéutico en los exosomas, y dirigir exosomas a un órgano, tejido o célula específico al usar las proteínas. Los métodos implican la generación de exosomas modificados genéticamente en la superficie que incluyen una o más de las proteínas de exosomas a densidad mayor, o una variante o un fragmento de la proteína de exosoma.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762550543P | 2017-08-25 | 2017-08-25 | |
US201862656956P | 2018-04-12 | 2018-04-12 | |
PCT/US2018/048026 WO2019040920A1 (en) | 2017-08-25 | 2018-08-24 | PREPARATION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINS |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020001790A true MX2020001790A (es) | 2020-07-22 |
Family
ID=65200359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020001790A MX2020001790A (es) | 2017-08-25 | 2018-08-24 | Preparacion de exosomas terapeuticos mediante el uso de proteinas de membrana. |
Country Status (15)
Country | Link |
---|---|
US (4) | US10195290B1 (es) |
EP (1) | EP3672573A4 (es) |
JP (2) | JP2020531018A (es) |
KR (2) | KR20200071065A (es) |
CN (1) | CN111212632B (es) |
AU (1) | AU2018321927A1 (es) |
BR (1) | BR112020003354A2 (es) |
CA (1) | CA3072352A1 (es) |
CL (1) | CL2020000428A1 (es) |
CO (1) | CO2020001872A2 (es) |
IL (1) | IL272786A (es) |
MX (1) | MX2020001790A (es) |
PH (1) | PH12020500308A1 (es) |
SG (1) | SG11202001008RA (es) |
WO (1) | WO2019040920A1 (es) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202001008RA (en) | 2017-08-25 | 2020-03-30 | Codiak Biosciences Inc | Preparation of therapeutic exosomes using membrane proteins |
EA202091134A1 (ru) * | 2017-12-28 | 2020-11-20 | Кодиак Байосайенсес, Инк. | Экзосомы для иммуноонкологической и противовоспалительной терапии |
CN111918967A (zh) | 2018-02-12 | 2020-11-10 | 科迪亚克生物科学公司 | 用于巨噬细胞极化的方法和组合物 |
JP2021518386A (ja) | 2018-03-23 | 2021-08-02 | コディアック バイオサイエンシーズ, インコーポレイテッド | Stingアゴニストを含む細胞外小胞 |
US20210262931A1 (en) * | 2018-06-21 | 2021-08-26 | Codiak Biosciences, Inc. | Methods of measuring extracellular vesicles and nanoparticles in complex matrices by light scattering |
WO2020041720A1 (en) | 2018-08-24 | 2020-02-27 | Codiak Biosciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
WO2020072699A1 (en) * | 2018-10-02 | 2020-04-09 | Exosome Therapeutics, Inc. | Exosome loaded therapeutics for treating sickle cell disease |
ES2907967T3 (es) | 2018-11-16 | 2022-04-27 | Codiak Biosciences Inc | Vesículas extracelulares modificadas y sus usos |
MX2021009337A (es) | 2019-02-04 | 2021-10-13 | Codiak Biosciences Inc | Cadenas principales de proteínas de la membrana para la modificación genética de exosomas. |
US20220144942A1 (en) | 2019-02-04 | 2022-05-12 | Codiak Biosciences, Inc. | Treatment of cancer metastasis by targeting exosome proteins |
CN114080232A (zh) | 2019-03-21 | 2022-02-22 | 科迪亚克生物科学公司 | 用于疫苗递送的细胞外囊泡 |
EP3941528A1 (en) | 2019-03-21 | 2022-01-26 | Codiak BioSciences, Inc. | Extracellular vesicle conjugates and uses thereof |
US20220387906A1 (en) | 2019-03-21 | 2022-12-08 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
WO2020191392A1 (en) * | 2019-03-21 | 2020-09-24 | Applied Stemcell, Inc. | Exosomes containing rna with specific mutation |
US20220218811A1 (en) * | 2019-04-17 | 2022-07-14 | Codiak Biosciences, Inc. | Methods of treating tuberculosis |
KR20220009389A (ko) | 2019-04-17 | 2022-01-24 | 코디악 바이오사이언시즈, 인크. | 엑소좀 및 aav 의 조성물 |
EP3974518A4 (en) * | 2019-05-21 | 2023-06-21 | H.U. Group Research Institute G.K. | PROCEDURE FOR WASHING EXTRACELLULAR VESICLE |
WO2021003425A1 (en) | 2019-07-03 | 2021-01-07 | Codiak Biosciences, Inc. | Methods of inducing hematopoiesis |
US20220251200A1 (en) | 2019-07-03 | 2022-08-11 | Codiak Biosciences, Inc. | Extracellular vesicles targeting t cells and uses thereof |
US20210093567A1 (en) * | 2019-08-06 | 2021-04-01 | Ohio State Innovation Foundation | Therapeutic extracellular vesicles |
US20230132093A1 (en) | 2019-08-14 | 2023-04-27 | Codiak Biosciences, Inc. | Extracellular vesicle-nlrp3 antagonist |
MX2022001769A (es) | 2019-08-14 | 2022-06-09 | Codiak Biosciences Inc | Construcciones de vesícula extracelular-oligonucleótido antisentido (aso) que se dirigen a la proteína beta de unión al potenciador ccaat (cebp)/beta. |
CN114729356A (zh) | 2019-08-14 | 2022-07-08 | 科迪亚克生物科学公司 | 靶向stat6的细胞外囊泡-aso构建体 |
WO2021030781A1 (en) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with antisense oligonucleotides targeting kras |
CN114728078A (zh) | 2019-08-14 | 2022-07-08 | 科迪亚克生物科学公司 | 与分子连接的细胞外囊泡及其用途 |
WO2021030768A1 (en) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with stat3-antisense oligonucleotides |
EP4022074A4 (en) * | 2019-08-27 | 2023-11-15 | The Trustees of Columbia University in the City of New York | GENETICALLY ENGINEERED EXOSOMES FOR TARGETED DELIVERY |
CN114727947A (zh) * | 2019-09-25 | 2022-07-08 | 科迪亚克生物科学公司 | 细胞外囊泡组合物 |
US20230241089A1 (en) | 2019-09-25 | 2023-08-03 | Codiak Biosciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
WO2021062057A1 (en) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Exogenous loading of exosomes via lyophilization |
US20230103726A1 (en) | 2019-09-25 | 2023-04-06 | Codiak Biosciences, Inc. | Methods of producing extracellular vesicles |
AU2020351729A1 (en) | 2019-09-25 | 2022-04-21 | Lonza Sales Ag | STING agonist comprising exosomes combined with IL-12 displaying exosomes for treating a tumour |
JP7402491B2 (ja) * | 2019-10-24 | 2023-12-21 | 国立大学法人広島大学 | エクソソームの単離方法、エクソソームの単離キット、およびエクソソームの除去方法 |
WO2021092193A1 (en) | 2019-11-05 | 2021-05-14 | Codiak Biosciences, Inc. | High-throughput chromatography screening for extracellular vesicles |
EP3845566A1 (en) * | 2019-12-30 | 2021-07-07 | Industrial Technology Research Institute | Extracellular vesicle separation method, colloidal particle and preparation method thereof |
WO2021146616A1 (en) | 2020-01-17 | 2021-07-22 | Codiak Biosciences, Inc. | Cholesterol assays for quantifying extracellular vesicles |
WO2021154888A1 (en) * | 2020-01-27 | 2021-08-05 | Mantra Bio. Inc. | Non-naturally occurring vesicles comprising a chimeric vesicle localization moiety, methods of making and uses thereof |
EP4099984A4 (en) | 2020-02-05 | 2024-05-01 | Diadem Biotherapeutics Inc | ARTIFICIAL SYNAPSES |
WO2021184020A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Methods of treating neuroinflammation |
JP2023517241A (ja) * | 2020-03-13 | 2023-04-24 | コディアック バイオサイエンシーズ, インコーポレイテッド | 細胞外ベシクルの標的送達 |
WO2021184021A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting pmp22 |
EP4117717A1 (en) | 2020-03-13 | 2023-01-18 | Codiak BioSciences, Inc. | Extracellular vesicles for treating neurological disorders |
AU2021236763A1 (en) | 2020-03-20 | 2022-10-06 | Lonza Sales Ag | Extracellular vesicles for therapy |
WO2021195154A1 (en) * | 2020-03-23 | 2021-09-30 | Avem Holdings, Llc | Isolation and purification of exosomes for regenerative medicine |
WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
US20230220068A1 (en) | 2020-06-05 | 2023-07-13 | Codiak Biosciences, Inc. | Anti-transferrin extracellular vesicles |
WO2022040223A1 (en) | 2020-08-17 | 2022-02-24 | Codiak Biosciences, Inc. | Methods of treating cancer |
WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
WO2022066928A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
EP4216993A2 (en) | 2020-09-23 | 2023-08-02 | Codiak BioSciences, Inc. | Methods of producing extracellular vesicles |
WO2022066934A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
WO2022076596A1 (en) | 2020-10-06 | 2022-04-14 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
CN113252616B (zh) * | 2021-01-29 | 2022-05-03 | 厦门大学 | 一种外泌体的糖基化研究方法 |
JP2024506712A (ja) | 2021-02-17 | 2024-02-14 | ロンザ セールス アーゲー | 細胞外ベシクルを負荷する方法 |
JP2024506711A (ja) | 2021-02-17 | 2024-02-14 | ロンザ セールス アーゲー | 最適化リンカー及びアンカー部分を介して生物学的に活性な分子に連結した細胞外ベシクル |
EP4294421A2 (en) | 2021-02-17 | 2023-12-27 | Lonza Sales AG | Extracellular vesicle-nlrp3 antagonist |
EP4304566A1 (en) | 2021-04-01 | 2024-01-17 | Lonza Sales AG | Extracellular vesicle compositions |
AU2022259546A1 (en) * | 2021-04-14 | 2023-11-16 | Anjarium Biosciences Ag | Fc-derived polypeptides |
CA3226019A1 (en) | 2021-07-20 | 2023-01-26 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their preparation, and uses |
WO2023027082A1 (ja) * | 2021-08-23 | 2023-03-02 | 積水化学工業株式会社 | ペプチド結合ハイブリッドリポソームエクソソーム、ペプチド結合エクソソーム、これらを含む組成物及びその形成方法 |
WO2023056468A1 (en) | 2021-09-30 | 2023-04-06 | Codiak Biosciences, Inc. | Extracellular vesicle comprising cholesterol tagged sting-agonist |
WO2023064924A1 (en) | 2021-10-14 | 2023-04-20 | Codiak Biosciences, Inc. | Modified producer cells for extracellular vesicle production |
CN113832003A (zh) * | 2021-10-20 | 2021-12-24 | 上海芙普瑞生物科技有限公司 | 一种便于提取制备脂肪干细胞外泌体的设备及提取工艺 |
WO2023091497A1 (en) * | 2021-11-16 | 2023-05-25 | Mayo Foundation For Medical Education And Research | Compositions and methods for tendon repair |
WO2023127645A1 (ja) * | 2021-12-28 | 2023-07-06 | 積水化学工業株式会社 | エクソソーム、それを形成するための方法、及びそれを含有する組成物 |
CN114112867A (zh) * | 2022-01-26 | 2022-03-01 | 天九再生医学(天津)科技有限公司 | 外泌体纯度分析方法 |
WO2023144127A1 (en) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon administration, and uses |
KR20230165196A (ko) * | 2022-05-24 | 2023-12-05 | 주식회사 시프트바이오 | 표면-개질된 세포외 소포체 및 이의 치료학적 용도 |
WO2023232976A1 (en) | 2022-06-03 | 2023-12-07 | Ags Therapeutics Sas | Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses |
WO2024065651A1 (zh) * | 2022-09-30 | 2024-04-04 | 谛邈生物科技(新加坡)有限公司 | 一种向adam10基因敲除的hek293细胞外泌体中装载二聚体cd24的方法 |
CN117802045A (zh) * | 2022-09-30 | 2024-04-02 | 北京恩康医药有限公司 | 一种工程化细胞外囊泡的构建及其应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747660A (en) | 1995-11-06 | 1998-05-05 | The University Of Colorado | Nucleic acid encoding prostaglandin F2α receptor regulatory protein |
MXPA02012198A (es) * | 2000-06-09 | 2004-08-19 | Teni Boulikas | Encapsulacion de polinucleotidos y drogas en liposomas objetivos. |
US20040049010A1 (en) | 2001-10-26 | 2004-03-11 | Warren Bridget A | Transmembrane proteins |
US7803906B2 (en) | 2002-03-22 | 2010-09-28 | Gene Signal International Sa | Composition comprising an angiogenesis related protein |
JP5129149B2 (ja) | 2005-10-31 | 2013-01-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 癌を処置および診断するための組成物および方法 |
US9085778B2 (en) | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
WO2012048372A1 (en) | 2010-10-11 | 2012-04-19 | Medsaic Pty Ltd | Assay for disease detection |
US9777042B2 (en) * | 2011-12-15 | 2017-10-03 | Morehouse School Of Medicine | Method of purifying HIV/SIV Nef from exosomal fusion proteins |
EP2922861A4 (en) * | 2012-11-26 | 2016-09-14 | Caris Life Sciences Switzerland Holdings Gmbh | BIOMARKER COMPOSITIONS AND METHODS |
EP3252160B1 (en) * | 2012-12-12 | 2020-10-28 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
WO2014138793A1 (en) | 2013-03-13 | 2014-09-18 | The University Of Queensland | A method of isolating cells for therapy and prophylaxis |
KR20150043937A (ko) | 2013-10-15 | 2015-04-23 | 삼성전자주식회사 | 개체의 간암 진단용 조성물, 개체의 간암 진단하는 방법 및 개체의 간암 진단에 필요한 정보를 얻는 방법 |
AU2015330855A1 (en) | 2014-10-09 | 2017-04-27 | Celularity Inc. | Placenta-derived adherent cell exosomes and uses thereof |
WO2016077639A2 (en) * | 2014-11-12 | 2016-05-19 | VL27, Inc. | Nanovesicular therapies |
WO2017075708A1 (en) * | 2015-11-05 | 2017-05-11 | Exerkine Corporation | Exosomes useful to treat cystic fibrosis |
WO2017117585A1 (en) | 2015-12-30 | 2017-07-06 | The Regents Of The University Of California | Methods for enhanced production and isolation of cell-derived vesicles |
EP3430024A4 (en) | 2016-03-15 | 2019-11-13 | Codiak BioSciences, Inc. | THERAPEUTIC MEMBRANE VESICLES |
US20200113943A1 (en) | 2017-06-05 | 2020-04-16 | The Regents Of The University Of California | Methods for enhanced production and isolation of cell-derived vesicles and treatment of inflammation and neurological damage |
SG11202001008RA (en) | 2017-08-25 | 2020-03-30 | Codiak Biosciences Inc | Preparation of therapeutic exosomes using membrane proteins |
-
2018
- 2018-08-24 SG SG11202001008RA patent/SG11202001008RA/en unknown
- 2018-08-24 CN CN201880055135.4A patent/CN111212632B/zh active Active
- 2018-08-24 KR KR1020207008265A patent/KR20200071065A/ko not_active Application Discontinuation
- 2018-08-24 EP EP18849251.6A patent/EP3672573A4/en active Pending
- 2018-08-24 US US16/112,547 patent/US10195290B1/en active Active
- 2018-08-24 CA CA3072352A patent/CA3072352A1/en active Pending
- 2018-08-24 KR KR1020247006118A patent/KR20240033086A/ko active Application Filing
- 2018-08-24 WO PCT/US2018/048026 patent/WO2019040920A1/en unknown
- 2018-08-24 MX MX2020001790A patent/MX2020001790A/es unknown
- 2018-08-24 BR BR112020003354-5A patent/BR112020003354A2/pt unknown
- 2018-08-24 JP JP2020510532A patent/JP2020531018A/ja active Pending
- 2018-08-24 AU AU2018321927A patent/AU2018321927A1/en active Pending
- 2018-12-21 US US16/231,012 patent/US10561740B2/en active Active
-
2019
- 2019-12-20 US US16/722,884 patent/US11679164B2/en active Active
-
2020
- 2020-02-11 PH PH12020500308A patent/PH12020500308A1/en unknown
- 2020-02-20 CL CL2020000428A patent/CL2020000428A1/es unknown
- 2020-02-20 IL IL272786A patent/IL272786A/en unknown
- 2020-02-20 CO CONC2020/0001872A patent/CO2020001872A2/es unknown
-
2022
- 2022-10-26 US US18/050,005 patent/US20240009322A1/en active Pending
-
2023
- 2023-09-13 JP JP2023148423A patent/JP2023160981A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190117792A1 (en) | 2019-04-25 |
BR112020003354A2 (pt) | 2020-08-18 |
US20190060483A1 (en) | 2019-02-28 |
CA3072352A1 (en) | 2019-02-28 |
WO2019040920A8 (en) | 2019-04-04 |
EP3672573A4 (en) | 2021-05-26 |
US20240009322A1 (en) | 2024-01-11 |
US20200222556A1 (en) | 2020-07-16 |
EP3672573A1 (en) | 2020-07-01 |
IL272786A (en) | 2020-04-30 |
PH12020500308A1 (en) | 2021-02-08 |
CN111212632B (zh) | 2024-04-16 |
AU2018321927A1 (en) | 2020-02-27 |
CO2020001872A2 (es) | 2020-06-19 |
CN111212632A (zh) | 2020-05-29 |
SG11202001008RA (en) | 2020-03-30 |
US11679164B2 (en) | 2023-06-20 |
WO2019040920A1 (en) | 2019-02-28 |
US10195290B1 (en) | 2019-02-05 |
JP2020531018A (ja) | 2020-11-05 |
JP2023160981A (ja) | 2023-11-02 |
US10561740B2 (en) | 2020-02-18 |
KR20240033086A (ko) | 2024-03-12 |
CL2020000428A1 (es) | 2020-11-27 |
KR20200071065A (ko) | 2020-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020500308A1 (en) | Preparation of therapeautic exosomes using membrane proteins | |
MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
MX2018006840A (es) | Focalizacion de peptidos para dirigir virus adenoasociados. | |
MX2022005291A (es) | Vacunas para el tratamiento y prevencion del cancer. | |
MX2021014448A (es) | Modulacion de celulas mieloides estimulantes y no estimulantes. | |
MX2018011836A (es) | Conjugados de anticuerpo farmaco anti-cd70. | |
MX2019009468A (es) | Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer. | |
WO2017222619A3 (en) | SEQUENCE ARRANGEMENTS AND SEQUENCES FOR THE PRESENTATION OF NEO-EPOPOPES | |
MX2018015853A (es) | Anticuerpos multiespecificos frente a los grupos de diferenciacion 40 y 137 (cd40 y cd137). | |
MX2021006017A (es) | Polipeptidos de folistatina y sus usos. | |
MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
NZ737471A (en) | Hydrophilic linkers for conjugation | |
EA201690016A1 (ru) | Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл | |
PH12018501335A1 (en) | Novel generation of antigen-specific tcrs | |
WO2013084000A3 (en) | Exosomes for delivery of biotherapeutics | |
TW201613636A (en) | Methods of treating Alzheimer's Disease | |
MX361259B (es) | Uso de un fragmento de peptido hmgb1 para el tratamiento del infarto al miocardio. | |
PH12014501363A1 (en) | Anticancer fusion protein | |
MX2018015110A (es) | Arn modificado que codifica polipeptidos de vegf-a. formulaciones y usos relacionados con los mismos. | |
MX2019003970A (es) | Péptidos de arginasa inmunogénicos. | |
MX2014004953A (es) | Ligadores basados en tirosina para la conexion desprendible de peptidos. | |
MX2021003773A (es) | Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos. | |
CO2017012675A2 (es) | Péptidos lipidados resistentes a proteasas | |
MX2018010196A (es) | Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas. | |
PH12019502449A1 (en) | Anti-jagged1 antigen binding proteins |